An interesting outcome was obtained from Re-MIND, an observational retrospective study that has evaluated the combination of tafasitamab (MOR208) with lenalidomide (Revlimid) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who were not eligible for high-dose chemotherapy and stem cell transplant.

This effect was already observed in the L-MIND trial, a single-arm open-label phase II, where 81 patients who had at least 1 to 3 prior lines of systemic treatment were enrolled and treated with a combination regimen (tafasitamab plus lenalidomide).

67 out of 490 patients with relapsed/refractory DLBCL, transplant ineligible, treated with single-agent Lenalidomide in the real-world setting for the Re-MIND study, were matched 1.1 to patients from the L-MIND trial. The objective response rate (ORR) was 67.1% in patients that received the combination regimen, a significant result compared to the 34.2% in those under the lenalidomide monotherapy treatment.

“Encouraged by the results we achieved with the real-world data approach, we re-affirm our plans to pursue the advancement of tafasitamab to market in combination with lenalidomide as a potential chemo-free treatment option for patients with r/r DLBCL, subject to FDA approval,” said Malte Peters, MD, chief development officer at MorphoSys AG (the manufacturer of tafasitamab).

.